BUZZ - Hims & Hers shares rise on potential sales of certain unapproved peptide products

October 28 - ** Hims & Hers Health (HIMS.N) shares rose 5% to $29.35 after the U.S. health authorities said they would temporarily allow (link) the sale of certain unapproved peptide products

** The telemedicine company HIMS stated that if regulations permit, the company plans to offer peptide products

** The interim policy covers six peptide substances, including the popular tissue repair compound BPC-157. Regulators are deciding on formally allowing its use in compounding medications

** Leerink analyst Michael Cherny indicated that this move, in theory, brings the market opportunity for these peptide drugs forward by at least several months

** However, he also cautioned: "This notice is still far from the 'green light' HIMS would need to fully capitalize on this opportunity"

** The stock is down 10.6% year to date

(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. These are provided solely for the convenience of readers. Reuters accepts no responsibility for any damages or losses arising from use of the automated translation feature.)